References
- Reilly J G, Ays S A, Ferrier I N, Jones S J, Thomas S H.L. QTc-interval abnormalities and psychotropic drug therapy in psychiatric patients. Lancet 2000; 355: 1048–1052
- Liberatore M A, Robinson D S. Torsade de pointes: a mechanism for sudden death associated with neuroleptic drug therapy?. Journal of Clinical Pharmacology 1984; 4: 143–146
- Royal College of Psychiatrists. The association between antipsychotic drugs and sudden death. Royal College of Psychiatrists, London 1997, Council report CR57
- Appleby L, Thomas S, Ferrier N, Lewis G, Shaw J, Amos T. Sudden unexplained death in psychiatric in-patients. British Journal of Psychiatry 2000; 176: 405–406
- Huston J R, Bell G E. The effect of thioridazine hydrochloride and chlorpromazine on the electrocardiogram. JAMA 1966; 198: 134–138
- Donatine B, Le Blaye I, Krupp P. Transient cardiac pacing is insufficiently used to treat arrhythmia associated with thioridazine. Cardiology 1992; 81: 340–341
- Mehtonen O P, Aranko K, Malkonen L, et al. Survey of sudden death associated with the use of antipsychotic or antidepressant drugs: 49 cases in Finland. Acta Psychiatrica Scandinavia 1991; 84: 58–64
- Rampe D, Murawsky M K, Grau J, Lewis E W. The antipsychotic agent sertindole is a high affinity antagonist of the human cardiac potassium channel HERG. Journal of Pharmacology and Experimental Therapeutics 1998; 286: 788–793
- Tie H, Walker B D, Valenzuela S M, Breit S N, Campbell T J. The heart of psychotropic drug therapy. Lancet 2000; 355: 1825
- Idle J R. The heart of psychotropic drug therapy. Lancet 2000; 355: 1824–1825
- Hancox J C, Witchel H J. Psychotropic drugs, HERG, and the heart. Lancet 2000; 356: 428
- Yap Y G, Camm J. Risk of torsades de pointes with non-cardiac drugs: doctors need to be aware that many drugs can cause QT prolongation. British Medical Journal 2000; 320: 1158–1159